Please select the option that best describes you:
Topics:
Gynecologic Cancers • Endometrial Cancer
Would you consider pembrolizumab plus lenvatinib for stage IV uterine carcinosarcoma after progression on chemotherapy as per Keynote-146 and now with Keynote-775?
Keynote-146 included 9 (17%) "other adenocarcinomas," but did not specifically exclude carcinosarcoma. Carcinosarcoma was specifically excluded from Keynote-775.
Answer from: at Academic Institution
Yes! Carcinosarcoma is considered a high-grade carcinoma (an epithelial neoplasm, and not a uterine sarcoma). The current FDA approved indication for lenvatinib and pembrolizumab is for those with advanced or recurrent disease that is not MSI-H or dMMR in patients who are not candidates for curative...
Sign in or Register to read more